Glycogen synthase kinase 3: An emerging therapeutic target

Hagit Eldar-Finkelman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

398 Scopus citations


Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase that has recently emerged as a key target in drug discovery. It has been implicated in multiple cellular processes and linked with the pathogenesis of several diseases. GSK-3 inhibitors might prove useful as therapeutic compounds in the treatment of conditions associated with elevated levels of enzyme activity, such as type 2 diabetes and Alzheimer's disease. The pro-apoptotic feature of GSK-3 activity suggests a potential role for its inhibitors in protection against neuronal cell death, and in the treatment of traumatic head injury and stroke. Finally, selective inhibitors of GSK-3 could mimic the action of mood stabilizers such as lithium and valproic acid and be used in the treatment of bipolar mood disorders.

Original languageEnglish
Pages (from-to)126-132
Number of pages7
JournalTrends in Molecular Medicine
Issue number3
StatePublished - 2002


Dive into the research topics of 'Glycogen synthase kinase 3: An emerging therapeutic target'. Together they form a unique fingerprint.

Cite this